Dec. 4 at 8:24 PM
Denali Therapeutics shares rose after announcing a
$275 million synthetic royalty financing deal with Royalty Pharma for its Hunter syndrome drug candidate, tividenofusp alfa. The agreement includes a
$200 million upfront payment and
$75 million tied to European approval by the end of 2029. Royalty Pharma will receive 9.25% royalties on global sales until reaching a return multiple, contingent on accelerated FDA approval. The FDA is reviewing the therapy with a target decision date of April 5, 2026. Denali’s CEO said the deal validates the drug’s potential and supports further development using its TransportVehicle technology to treat cognitive and physical symptoms of Hunter syndrome.
$DNLI $RPRX